See more : REINO Capital S.A. (RNC.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Marrone Bio Innovations, Inc. (MBII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marrone Bio Innovations, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Catskill Hudson Bancorp, Inc. (CSKL) Income Statement Analysis – Financial Results
- Tekkorp Digital Acquisition Corp. (TEKKU) Income Statement Analysis – Financial Results
- Sapphire Foods India Limited (SAPPHIRE.BO) Income Statement Analysis – Financial Results
- Hangzhou Lianluo Interactive Information Technology Co.,Ltd (002280.SZ) Income Statement Analysis – Financial Results
- Formosa Sumco Technology Corporation (3532.TW) Income Statement Analysis – Financial Results
Marrone Bio Innovations, Inc. (MBII)
About Marrone Bio Innovations, Inc.
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.31M | 100.00K | 29.37M | 21.22M | 18.17M | 14.04M | 9.80M | 9.14M | 14.54M | 7.14M | 5.25M |
| Cost of Revenue | 17.06M | 40.00K | 13.26M | 10.91M | 10.53M | 9.52M | 9.26M | 9.44M | 10.74M | 4.33M | 2.17M |
| Gross Profit | 27.25M | 60.00K | 16.11M | 10.31M | 7.64M | 4.52M | 545.00K | -302.00K | 3.81M | 2.81M | 3.08M |
| Gross Profit Ratio | 61.49% | 60.00% | 54.86% | 48.60% | 42.05% | 32.19% | 5.56% | -3.31% | 26.18% | 39.31% | 58.64% |
| Research & Development | 12.08M | 30.00K | 14.03M | 10.66M | 10.82M | 9.67M | 13.50M | 19.28M | 17.81M | 12.74M | 9.41M |
| General & Administrative | 0.00 | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.57M | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.29M | 6.79M |
| Operating Expenses | 42.65M | 105.00K | 44.10M | 29.82M | 30.63M | 28.18M | 40.00M | 48.23M | 32.83M | 23.04M | 16.20M |
| Cost & Expenses | 59.71M | 145.00K | 57.36M | 40.72M | 41.16M | 37.70M | 49.26M | 57.67M | 43.57M | 27.37M | 18.38M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 37.00K | 51.00K | 59.00K | 49.00K | 16.00K | 22.00K |
| Interest Expense | 1.57M | 4.00K | 1.47M | 2.51M | 7.73M | 7.30M | 4.36M | 2.91M | 6.00M | 2.47M | 88.00K |
| Depreciation & Amortization | 4.57M | 3.56M | 3.15M | 1.89M | 2.04M | 2.24M | 3.51M | 2.58M | 976.00K | 613.00K | 499.00K |
| EBITDA | -10.37M | 3.51M | -32.53M | -15.82M | -21.15M | -21.53M | -35.86M | -46.17M | -21.52M | -35.72M | -12.59M |
| EBITDA Ratio | -23.41% | 3,509.00% | -110.75% | -74.53% | -116.43% | -153.35% | -365.83% | -505.37% | -147.95% | -500.21% | -239.82% |
| Operating Income | -14.94M | -17.20M | -27.99M | -19.50M | -23.00M | -23.66M | -39.46M | -48.53M | -29.03M | -23.84M | -13.12M |
| Operating Income Ratio | -33.71% | -17,195.00% | -95.27% | -91.91% | -126.58% | -168.49% | -402.58% | -531.23% | -199.58% | -333.87% | -249.93% |
| Total Other Income/Expenses | -1.57M | 17.14M | -9.19M | -709.00K | -7.93M | -7.41M | -4.27M | -3.13M | 536.00K | -14.96M | -56.00K |
| Income Before Tax | -16.51M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Income Before Tax Ratio | -37.26% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| Income Tax Expense | 45.00K | 17.15M | 15.00K | 1.80M | -201.00K | -109.00K | 92.00K | -219.00K | 6.53M | -12.49M | 32.00K |
| Net Income | -16.55M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Net Income Ratio | -37.36% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| EPS | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.26 | -2.12 | -0.72 |
| EPS Diluted | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.20 | -2.12 | -0.72 |
| Weighted Avg Shares Out | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.73M | 18.27M | 18.27M |
| Weighted Avg Shares Out (Dil) | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.91M | 18.27M | 18.27M |
Marrone Bio Appoints Sue Cheung New Chief Financial Officer
Global Adoption of Biologicals Accelerates as Marrone Bio's Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in the U.S.
Marrone Bio Innovations Announces Effectiveness of Form S-3 Resale Registration Statement
Marrone Bio Provides Update on Warrant Transactions; No New Securities Offered
PGG Wrightson Seeds to Distribute Marrone Bio Innovations' Pro Farm UBP Seed Treatment in Uruguay
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q3 2020 Results - Earnings Call Transcript
Marrone Bio Innovations, Inc. Reports Third-Quarter 2020 Financial Results
Marrone Bio Innovations's Earnings Outlook
Marrone Bio Innovations to Report Third Quarter 2020 Results on Monday, November 9th at 4:30 p.m. Eastern Time
Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update
Source: https://incomestatements.info
Category: Stock Reports